282 related articles for article (PubMed ID: 34032767)
1. Long-term response on letrozole for gastric cancer: A case report.
Iida Y; Hongo K; Onoda T; Kita Y; Ishihara Y; Takabayashi N; Kobayashi R; Kuriki K; Hiramatsu T
Medicine (Baltimore); 2021 May; 100(21):e26146. PubMed ID: 34032767
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Pater JL
J Natl Cancer Inst; 2005 Sep; 97(17):1262-71. PubMed ID: 16145047
[TBL] [Abstract][Full Text] [Related]
3. Rare case of ER positive colorectal stricture demonstrating improvement with letrozole.
Paleja M; Gorthi G; Scott H; Johnson T
BMJ Case Rep; 2011 Dec; 2011():. PubMed ID: 22674946
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
[TBL] [Abstract][Full Text] [Related]
5. Late distant recurrence of breast carcinoma and metastasis to the main bronchus and choroid: A case report.
Luo Z; Cai Q; Zhao Y; Wang X; Fu S; Zhai L
Medicine (Baltimore); 2018 May; 97(20):e10754. PubMed ID: 29768356
[TBL] [Abstract][Full Text] [Related]
6. Palbociclib with letrozole as second-line neo-systemic therapy after failure of neo-adjuvant chemotherapy for luminal type breast cancer: A case report.
Jung SU; Jung M; Choi JH; Jeon CW
Medicine (Baltimore); 2021 Apr; 100(14):e25175. PubMed ID: 33832078
[TBL] [Abstract][Full Text] [Related]
7. [Indoleamine 2,3-Dioxygenase Activity during Long-Term Letrozole Therapy for Hormone Receptor-Positive Breast Cancer].
Suzuki Y; Sakurai K; Adachi K; Kubota H; Suzuki S; Takei S; Hara Y; Enomoto K; Hirano T; Makishima M
Gan To Kagaku Ryoho; 2018 Oct; 45(10):1495-1497. PubMed ID: 30382056
[TBL] [Abstract][Full Text] [Related]
8. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
Sujarittanakarn S; Himakhun W; Worasawate W; Prasert W
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1559-1565. PubMed ID: 32592349
[TBL] [Abstract][Full Text] [Related]
9. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
Ellis MJ; Coop A; Singh B; Mauriac L; Llombert-Cussac A; Jänicke F; Miller WR; Evans DB; Dugan M; Brady C; Quebe-Fehling E; Borgs M
J Clin Oncol; 2001 Sep; 19(18):3808-16. PubMed ID: 11559718
[TBL] [Abstract][Full Text] [Related]
10. Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial.
Leone JP; Cole BF; Regan MM; Thürlimann B; Coates AS; Rabaglio M; Giobbie-Hurder A; Gelber RD; Ejlertsen B; Harvey VJ; Neven P; Láng I; Bonnefoi H; Wardley A; Goldhirsch A; Di Leo A; Colleoni M; Vaz-Luis I; Lin NU
Cancer; 2021 Mar; 127(5):700-708. PubMed ID: 33290610
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea.
Beom SH; Oh J; Kim TY; Lee KH; Yang Y; Suh KJ; Moon HG; Han SW; Oh DY; Han W; Kim TY; Noh DY; Im SA
Cancer Res Treat; 2017 Apr; 49(2):454-463. PubMed ID: 27554482
[TBL] [Abstract][Full Text] [Related]
12. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
Colleoni M; Luo W; Karlsson P; Chirgwin J; Aebi S; Jerusalem G; Neven P; Hitre E; Graas MP; Simoncini E; Kamby C; Thompson A; Loibl S; Gavilá J; Kuroi K; Marth C; Müller B; O'Reilly S; Di Lauro V; Gombos A; Ruhstaller T; Burstein H; Ribi K; Bernhard J; Viale G; Maibach R; Rabaglio-Poretti M; Gelber RD; Coates AS; Di Leo A; Regan MM; Goldhirsch A;
Lancet Oncol; 2018 Jan; 19(1):127-138. PubMed ID: 29158011
[TBL] [Abstract][Full Text] [Related]
13. Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2.
Rugo HS; Finn RS; Gelmon K; Joy AA; Harbeck N; Castrellon A; Mukai H; Walshe JM; Mori A; Gauthier E; Lu DR; Bananis E; Martin M; Diéras V
Clin Breast Cancer; 2020 Apr; 20(2):e173-e180. PubMed ID: 31836434
[TBL] [Abstract][Full Text] [Related]
14. [A case of metastatic gastric cancer originating from transverse colon cancer].
Nushijima Y; Nakano K; Sugimoto K; Nakaguchi K; Kan K; Maruyama H; Doi S; Okamura S; Murata K
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1802-4. PubMed ID: 25731335
[TBL] [Abstract][Full Text] [Related]
15. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
Iwata H; Masuda N; Yamamoto Y; Fujisawa T; Toyama T; Kashiwaba M; Ohtani S; Taira N; Sakai T; Hasegawa Y; Nakamura R; Akabane H; Shibahara Y; Sasano H; Yamaguchi T; Sakamaki K; Bailey H; Cherbavaz DB; Jakubowski DM; Sugiyama N; Chao C; Ohashi Y
Breast Cancer Res Treat; 2019 Jan; 173(1):123-133. PubMed ID: 30242578
[TBL] [Abstract][Full Text] [Related]
16. [Clinical Efficacy of Alternate-Day S-1/Letrozole Combination Therapy for Advanced Breast Cancer with Gastric Metastasis--A Case Report].
Nakayama I; Muranishi Y; Fujita Y
Gan To Kagaku Ryoho; 2015 Jul; 42(7):851-4. PubMed ID: 26197748
[TBL] [Abstract][Full Text] [Related]
17. Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment.
Bell T; Crown JP; Lang I; Bhattacharyya H; Zanotti G; Randolph S; Kim S; Huang X; Huang Bartlett C; Finn RS; Slamon D
Curr Med Res Opin; 2016 May; 32(5):959-65. PubMed ID: 26894413
[TBL] [Abstract][Full Text] [Related]
18. Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
Luen SJ; Asher R; Lee CK; Savas P; Kammler R; Dell'Orto P; Biasi OM; Demanse D; JeBailey L; Dolan S; Hackl W; Thuerlimann B; Viale G; Colleoni M; Regan MM; Loi S
JAMA Oncol; 2018 Oct; 4(10):1335-1343. PubMed ID: 29902286
[TBL] [Abstract][Full Text] [Related]
19. Clinical response to primary letrozole therapy in elderly patients with early breast cancer: possible role for p53 as a biomarker.
Garimella V; Hussain T; Agarwal V; Radhakrishna S; Fox JN; Kneeshaw PJ; Long ED; Mahapatra TK; McManus PL; Lind MJ; Drew PJ; Cawkwell L
Int J Surg; 2014; 12(8):821-6. PubMed ID: 25010604
[TBL] [Abstract][Full Text] [Related]
20. Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial.
Skriver SK; Jensen MB; Knoop AS; Ejlertsen B; Laenkholm AV
Breast Cancer Res; 2020 May; 22(1):46. PubMed ID: 32410705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
